In the competitive world of healthcare, the patient experience extends beyond the examination room. One critical, yet often overlooked aspect is the billing experience. While medical practitioners focus primarily on the quality of care, the final interactions that patients often remember are
Gene therapy has ushered in a new era of medical possibilities, offering groundbreaking treatments for debilitating and often fatal diseases. One of the most prominent examples is Lenmeldy (atidarsagene autotemcel), a gene therapy developed by Orchard Therapeutics and recently acquired by Kyowa
In a recent turn of events, the National Health Service (NHS) in England has declined to approve the Alzheimer's treatment lecanemab, co-developed by Eisai Co. and Biogen Inc., primarily due to financial considerations. This decision comes despite the drug receiving authorization from the
The UK healthcare system has made notable strides in the realm of Advanced Therapy Medicinal Products (ATMPs), which include cutting-edge cell and gene therapies. These advanced treatments offer transformative benefits for patients with rare diseases, providing hope and significant improvements in
Cell and gene therapy hold tremendous promise for treating a wide array of diseases, including many that were previously considered untreatable. However, the high production costs associated with these advanced treatments pose a significant barrier to their widespread adoption. Automation emerges
The fields of cell and gene therapy have seen remarkable advancements and transformative updates over the past few years. As biotechnology companies strive to innovate and deliver groundbreaking solutions, significant milestones have been achieved, fostering hope and optimism for addressing some of
